Fabric Genomics provides AI software that helps clinical labs and hospitals interpret genomic tests, prioritize variants, and automate diagnostic reports.
Fabric Genomics is a clinical genomics software company that builds AI-assisted tools for interpreting DNA sequencing data. Rather than performing sequencing itself, the platform sits downstream of a lab's sequencer and helps geneticists and clinicians make sense of the enormous number of genetic variants a single genome or exome produces, narrowing them down to a short, clinically relevant list a physician can act on.
Founded in 2009 and based in Oakland, California, the company was previously known as Omicia before rebranding as Fabric Genomics. It works with hospital genetics departments, commercial diagnostic laboratories, and national or state-level genome sequencing initiatives, and its technology has been applied to use cases ranging from rare disease diagnosis in children to rapid genetic testing in neonatal intensive care units. In 2025, Fabric Genomics was acquired by GeneDx, a diagnostics company, which it describes as the start of a new phase for AI-powered testing at larger scale.
The platform's central function is automated variant prioritization: it applies AI models and ACMG guideline-based classification to rank the variants found in a genome or exome by their likely clinical significance, cutting down the manual review time geneticists would otherwise spend sorting through thousands of variants per patient. Published results from a partnership with Rady Children's Hospital reported roughly 98 percent accuracy in variant-calling for certain diagnostic workflows.
Fabric Genomics also automates report generation, producing structured, physician-ready output rather than raw variant lists, and it is built to scale from single-patient tests up to sequencing programs processing hundreds of thousands of samples, which is relevant for national genomic screening initiatives. Its cloud architecture and explainable-AI approach are aimed at letting clinical labs add genomic testing capacity without proportionally growing headcount.
Fabric Genomics does not publish self-serve pricing. As an enterprise clinical software vendor, it sells through a sales-assisted process: prospective customers request a demo or an implementation assessment, and pricing is negotiated based on sample volume, deployment type, and the specific diagnostic workflows a lab needs to support.
This model is typical for clinical and regulatory-adjacent software sold to hospitals and diagnostic labs, where contracts often include validation, integration with existing lab information systems, and ongoing clinical support rather than a simple subscription tier.
It provides AI software that interprets genomic sequencing data, prioritizing variants and automating diagnostic report generation for clinical labs and hospitals.
Pricing is not public. The company sells through a demo and custom implementation assessment based on a lab's sample volume and workflow needs.
Its customers are hospital genetics departments, children's medical centers, commercial diagnostic laboratories, and national genome sequencing programs.
No. Fabric Genomics was acquired by GeneDx in 2025 and now operates as part of that diagnostics company.
No, it interprets sequencing data produced by a lab's own sequencers rather than performing the sequencing.